INNOVATION PARTNERSHIPS

Covalent Small-Molecule Inhibitors of DCN1

Protein

TECHNOLOGY NUMBER: 7456



OVERVIEW

Small molecule inhibitors that influence dysregulation of intracellular proteins

- Strong, covalent bonding of the inhibitor to the UBC12-DCN1 binding site
- Useful for oxidative stress diseases as well as nerve and muscle degeneration

BACKGROUND

Cellular protein homeostasis involves the regulated destruction of intracellular proteins by the ubiquitin-proteasome system (UPS). Cullin-Ring ligases (CRL) are a central component of the UPS, and their dysregulation can cause illnesses including cancer, cardiovascular disease, neurodegenerative disorders, and viral infections. A ligase named DCN1 acts as a scaffolding to facilitate other enzymes including UBC12 in their efforts to identify and destroy cellular proteins. DCN1 maintains a shape that provides a well-defined pocket for use as a binding surface for interactions between protein-regulating enzymes. A need exists to find small molecule inhibitors of the UBC12-DCN1 protein interaction in an effort to treat diseases associated with dysregulation of the UPS.

INNOVATION

University of Michigan researchers have discovered a method for producing small molecule inhibitors that can bind with the site in DCN1 bonds with UBC12, thereby causing inhibition of the UBC12-DCN1 protein to protein interactions and providing a method for treating diseases caused by UPS dysregulation. The inhibitors form a strong, or covalent, bond with the DCN1

Technology ID

7456

Category

Therapeutics and Vaccines Life Sciences

Inventor

Haibin Zhou Jeanne Stuckey Jianfeng Lu Liangyou Rui Liu Liu Shaomeng Wang Yi Sun

Further information

Tiefei Dong tiefeid@umich.edu

Learn more



binding site to modulate the effects of Cullin-Ring ligases and cause preservation of certain proteins which may otherwise inappropriately be destroyed in certain diseases. The ability of compounds of this invention to covalently bind to DCN1 for inhibition of the interaction between DCN1 and UBC12 leads to a highly consequential boost in potency as compared to their non-covalent inhibitor counterparts. The benefits of this type of interaction can extend to patients with oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration.